Covered recipient · General Payments record
LAWRENCE F EICHENFIELD
Allopathic & Osteopathic Physicians Dermatology Pediatric Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$428,654.73
369 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $289,646.20 | 58 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $65,556.62 | 38 |
| Travel and Lodging | $59,103.45 | 130 |
| Honoraria | $7,650.00 | 1 |
| Food and Beverage | $6,698.46 | 142 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| LEO Pharma AS | $99,054.72 | 51 |
| Regeneron Healthcare Solutions, Inc. | $74,009.24 | 62 |
| PFIZER INC. | $54,804.89 | 44 |
| Almirall LLC | $40,601.05 | 19 |
| DERMIRA, INC. | $34,882.06 | 39 |
| GENZYME CORPORATION | $33,893.12 | 35 |
| Eli Lilly and Company | $28,008.28 | 20 |
| SANOFI-AVENTIS U.S. LLC | $21,116.77 | 25 |
| Regeneron Pharmaceuticals, Inc. | $11,068.65 | 6 |
| ABBVIE INC. | $9,400.71 | 25 |
| Lilly USA, LLC | $8,263.50 | 8 |
| Novartis Pharmaceuticals Corporation | $5,406.81 | 2 |
| UCB SA | $3,647.45 | 13 |
| Promius Pharma LLC | $1,731.97 | 2 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $1,661.71 | 8 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $600.00 | 1 |
| LEO Pharma Inc. | $256.07 | 4 |
| ALK-Abello, Inc | $166.62 | 1 |
| Sun Pharmaceutical Industries Inc. | $58.01 | 2 |
| Galderma Laboratories, L.P. | $13.66 | 1 |
| Pierre Fabre Pharmaceuticals, Inc. | $9.44 | 1 |
Page 3 of 8; records 101–150 of 369 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LAWRENCE F EICHENFIELD
NPI 1477624138 · CMS profile ID 339077
Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology
SAN DIEGO, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 8; records 101–150 of 369 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1477624138?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LAWRENCE F EICHENFIELD, NPI 1477624138, CMS profile ID 339077. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 369 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1477624138?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). LAWRENCE F EICHENFIELD, NPI 1477624138, CMS profile ID 339077. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 369 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1477624138?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- LAWRENCE F EICHENFIELD, NPI 1477624138, CMS profile ID 339077, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 8; records 101–150 of 369 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1477624138?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
369 matching records · $428,654.73 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 369.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $104.98 | 08/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659025477 | CMS |
| PFIZER INC. | $330.00 | 08/28/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673785533 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,787.50 | 08/28/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373633 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $22.18 | 08/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684575891 | CMS |
| PFIZER INC. | $2,550.00 | 08/23/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673203665 | CMS |
| DERMIRA, INC. | $780.00 | 08/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703882319 | CMS |
| Eli Lilly and Company | $390.49 | 08/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657954471 | CMS |
| Eli Lilly and Company | $31.38 | 08/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657954473 | CMS |
| Eli Lilly and Company | $11.29 | 08/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657964779 | CMS |
| PFIZER INC. | $18.60 | 08/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673201467 | CMS |
| DERMIRA, INC. | $3,750.00 | 08/14/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703882321 | CMS |
| GENZYME CORPORATION | $3,861.00 | 08/12/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694328671 | CMS |
| PFIZER INC. | $7,800.00 | 08/12/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673211533 | CMS |
| PFIZER INC. | $7,800.00 | 08/12/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673223265 | CMS |
| DERMIRA, INC. | $53.62 | 08/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703880273 | CMS |
| DERMIRA, INC. | $26.62 | 08/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703885443 | CMS |
| Almirall LLC | $10.47 | 08/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676653799 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,342.00 | 08/05/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373631 | CMS |
| Regeneron Healthcare Solutions, Inc. | $48.27 | 07/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373621 | CMS |
| Regeneron Healthcare Solutions, Inc. | $40.49 | 07/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373623 | CMS |
| Regeneron Healthcare Solutions, Inc. | $18.85 | 07/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373625 | CMS |
| Regeneron Healthcare Solutions, Inc. | $78.44 | 07/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373627 | CMS |
| Regeneron Healthcare Solutions, Inc. | $28.92 | 07/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373629 | CMS |
| ALK-Abello, Inc | $166.62 | 07/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698051161 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $56.06 | 07/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684575889 | CMS |
| PFIZER INC. | $798.30 | 07/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673212393 | CMS |
| PFIZER INC. | $492.96 | 07/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673214687 | CMS |
| PFIZER INC. | $130.60 | 07/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673221643 | CMS |
| Regeneron Healthcare Solutions, Inc. | $5.44 | 07/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373617 | CMS |
| Regeneron Healthcare Solutions, Inc. | $118.81 | 07/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373619 | CMS |
| PFIZER INC. | $539.44 | 07/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673217785 | CMS |
| PFIZER INC. | $160.04 | 07/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673224239 | CMS |
| Sun Pharmaceutical Industries Inc. | $37.62 | 07/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704584611 | CMS |
| Almirall LLC | $3,400.00 | 07/16/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676653795 | CMS |
| Eli Lilly and Company | $7,125.00 | 07/02/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657954469 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,342.00 | 07/01/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373615 | CMS |
| LEO Pharma AS | $5.47 | 06/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687252017 | CMS |
| LEO Pharma AS | $13,755.00 | 06/27/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687252019 | CMS |
| LEO Pharma AS | $151.18 | 06/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687252021 | CMS |
| Almirall LLC | $116.53 | 06/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676653793 | CMS |
| PFIZER INC. | $22.16 | 06/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673213761 | CMS |
| Regeneron Healthcare Solutions, Inc. | $8,580.00 | 06/12/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373599 | CMS |
| Regeneron Healthcare Solutions, Inc. | $7.95 | 06/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373601 | CMS |
| Regeneron Healthcare Solutions, Inc. | $38.00 | 06/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373603 | CMS |
| Regeneron Healthcare Solutions, Inc. | $67.26 | 06/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373605 | CMS |
| Regeneron Healthcare Solutions, Inc. | $7.95 | 06/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373607 | CMS |
| Regeneron Healthcare Solutions, Inc. | $3.97 | 06/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373609 | CMS |
| Regeneron Healthcare Solutions, Inc. | $169.00 | 06/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373611 | CMS |
| Regeneron Healthcare Solutions, Inc. | $4,290.00 | 06/12/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673373613 | CMS |
| SANOFI-AVENTIS U.S. LLC | $265.00 | 06/12/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694056511 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $22,322.51 | 24 |
| PY2025 | Principal investigator | $22,565.28 | 6 |
| PY2024 | Recipient | $25,085.81 | 30 |
| PY2024 | Principal investigator | $23,094.68 | 41 |
| PY2023 | Recipient | $26,185.13 | 33 |
| PY2023 | Principal investigator | $75,506.72 | 64 |
| PY2022 | Recipient | $22,411.76 | 23 |
| PY2022 | Principal investigator | $73,901.97 | 39 |
| PY2021 | Recipient | $23,442.77 | 43 |
| PY2021 | Principal investigator | $108,046.83 | 58 |
| PY2020 | Recipient | $16,080.92 | 16 |
| PY2020 | Principal investigator | $128,050.86 | 35 |
| PY2019 | Recipient | $8,602.94 | 9 |
| PY2019 | Principal investigator | $99,280.80 | 13 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
30 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | Regeneron Pharmaceuticals, Inc. | $416.67 | 12/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184117347 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $275.00 | 12/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184117349 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $275.00 | 12/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184117351 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $928.64 | 11/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184117345 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $1,488.00 | 10/29/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFORNIA | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234517335 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $4,225.00 | 10/29/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFORNIA | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234517338 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $2,000.00 | 10/29/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFORNIA | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234517343 |
| Recipient | GENZYME CORPORATION | $500.00 | 10/24/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226089379 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $8,710.00 | 09/26/2025 | Non-covered Recipient Entity University of CA San Diego | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163822 |
| Recipient | GENZYME CORPORATION | $500.00 | 09/17/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226089350 |
| Recipient | PFIZER INC. | $940.00 | 09/17/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727561 |
| Recipient | GENZYME CORPORATION | $500.00 | 06/26/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226089338 |
| Recipient | GENZYME CORPORATION | $250.00 | 06/26/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226089361 |
| Recipient | GENZYME CORPORATION | $250.00 | 06/25/2025 | Covered Recipient Physician | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226089374 |
| Recipient | GENZYME CORPORATION | $500.00 | 06/17/2025 | Covered Recipient Physician | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226089331 |
| Recipient | GENZYME CORPORATION | $250.00 | 06/17/2025 | Covered Recipient Physician | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226089344 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $851.25 | 05/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184117343 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $741.07 | 04/01/2025 | Covered Recipient Physician | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184117339 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $668.22 | 04/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184117341 |
| Recipient | Amgen Inc. | $10,124.55 | 03/12/2025 | Covered Recipient Physician | A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1246637010 |
| Recipient | GENZYME CORPORATION | $500.00 | 03/07/2025 | Covered Recipient Physician | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226089355 |
| Recipient | GENZYME CORPORATION | $250.00 | 03/07/2025 | Covered Recipient Physician | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226089368 |
| Principal investigator 1 | ABBVIE INC. | $1,880.95 | 03/06/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202457779 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $670.68 | 03/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184117327 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $190.38 | 03/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184117329 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,021.50 | 03/01/2025 | Covered Recipient Physician | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184117331 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $340.91 | 03/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184117333 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $450.00 | 03/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184117335 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $928.64 | 03/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184117337 |
| Principal investigator 1 | Amgen Inc. | $4,261.33 | 02/27/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA AT SAN DIEGO RADY CHILDRENS HOSPITAL SAN DIEGO | A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) | No dispute reported | 06/30/2026 | 1246650199 |